腔内动脉瘤封堵术与腔内动脉瘤修复术后的生存率比较
本研究为两中心回顾性观察研究,纳入2011年1月至2018年4月择期治疗的564例无症状肾下腹主动脉瘤患者(EVAS 225例,EVAR 369例),倾向性评分匹配后两组各207例。中位随访49个月(EVAS)和44个月(EVAR),两组全因死亡(20.8% vs 25.1%,p=0.293)及动脉瘤相关死亡、心血管死亡均无显著差异,5年生存率相近(EVAS 74.9%,EVAR 75.5%)。
要点
- EVAS与EVAR在全因死亡、动脉瘤相关死亡及心血管死亡上均无显著差异。
- EVAS组1年生存率95.5%、5年生存率74.9%;EVAR组分别为93.3%和75.5%。
- EVAR组术后前2年炎症反应(白细胞、血小板)有偏高趋势,但随访期无显著差异。
核心结论
- EVAS与EVAR在5年随访期内生存率相当,EVAR患者术后前2年炎症反应有偏高趋势。
研究设计与样本
- 两中心回顾性观察研究,纳入2011年1月至2018年4月择期治疗的564例无症状肾下腹主动脉瘤患者(EVAS 225例,EVAR 369例)。
- 倾向性评分匹配后两组各207例,EVAS组中位随访49个月,EVAR组44个月。
主要发现
- EVAS组死亡43例(20.8%),EVAR组52例(25.1%),p=0.293。
- 动脉瘤相关死亡4例(EVAS 3例,EVAR 1例,p=0.222),心血管死亡14例(EVAS 6例,EVAR 8例,p=0.845)。
- EVAS组1年生存率95.5%、5年生存率74.9%;EVAR组1年93.3%、5年75.5%。
- EVAR组术前白细胞计数较高(p=0.011),术前血小板计数较低(p=0.001),但1年随访时血小板计数显著较高(p=0.003)。
- 两组死因无显著差异。
临床怎么用
- 对于无症状肾下腹主动脉瘤择期治疗,EVAS与EVAR的5年生存率相当,选择术式时可结合解剖条件和炎症反应倾向综合考量。
局限性
- 本研究为回顾性观察研究,仅纳入两中心数据,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Endovascular aneurysm sealing (EVAS) is a sac-filling device with a blunted systemic inflammatory response compared to conventional endovascular aneurysm repair (EVAR), with a suggested impact on all-cause mortality. This study compares mortality after both EVAS and EVAR. MATERIALS AND METHODS: This is a retrospective observational study including data from 2 centres, with ethical approval. Elective procedures on asymptomatic infrarenal aneurysms performed between January 2011 until April 2018 were enrolled. Laboratory values (serum creatinine, haemoglobin, white blood cell count, platelet count) were measured pre- and postoperatively and at 1 and 2 years, respectively. Mortality and cause of death were recorded during follow-up. RESULTS: A total of 564 patients were included (225 EVAS, 369 EVAR), after propensity score matching there were 207 patients in both groups. Baseline characteristics were similar, except for larger neck angulation and more pulmonary disease in the EVAR group. The median follow-up time was 49 (EVAS) and 44 (EVAR) months. No significant differences regarding creatinine and haemoglobin were observed. Preoperative white blood cell count was higher in the EVAR group (p=0.011), without significant differences during follow-up. Median platelet count was lower in the EVAR group preoperatively (p=0.001), but was significantly higher at 1 year follow-up (p=0.003). There were 43 deaths within the EVAS group (20.8%) and 52 within the EVAR group (25.1%) (p=0.293). Of these, 4 were aneurysm related (EVAS n=3, EVAR n=1; p=0.222) and 14 cardiovascular (EVAS n=6, EVAR n=8, p=0.845). For the EVAS cohort, survival was 95.5% at 1 year and 74.9% at 5 years. For the EVAR cohort, this was 93.3% at 1 year and 75.5% at 5 years. No significant differences were observed in causes of death. CONCLUSION: This study showed comparable survival rates through 5 years between EVAS and EVAR with a tendency toward higher inflammatory response in the EVAR patients through the first 2 years.
引用
- Zoethout AC, Sheriff A, Zeebregts CJ, et al. Survival After Endovascular Aneurysm Sealing Compared With Endovascular Aneurysm Repair. J Endovasc Ther. 2021. PMID: 34152230. doi:10.1177/15266028211025030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。